key: cord-0077496-0uda74qw authors: Bolivar-Wagers, Sara; Larson, Jemma H.; Jin, Sujeong; Blazar, Bruce R. title: Cytolytic CD4(+) and CD8(+) Regulatory T-Cells and Implications for Developing Immunotherapies to Combat Graft-Versus-Host Disease date: 2022-04-12 journal: Front Immunol DOI: 10.3389/fimmu.2022.864748 sha: 497244d5f08a4f5d48cf92f661e636a92d296a55 doc_id: 77496 cord_uid: 0uda74qw Regulatory T-cells (Treg) are critical for the maintenance of immune homeostasis and tolerance induction. While the immunosuppressive mechanisms of Treg have been extensively investigated for decades, the mechanisms responsible for Treg cytotoxicity and their therapeutic potential in regulating immune responses have been incompletely explored and exploited. Conventional cytotoxic T effector cells (Teffs) are known to be important for adaptive immune responses, particularly in the settings of viral infections and cancer. CD4+ and CD8+ Treg subsets may also share similar cytotoxic properties with conventional Teffs. Cytotoxic effector Treg (cyTreg) are a heterogeneous population in the periphery that retain the capacity to suppress T-cell proliferation and activation, induce cellular apoptosis, and migrate to tissues to ensure immune homeostasis. The latter can occur through several cytolytic mechanisms, including the Granzyme/Perforin and Fas/FasL signaling pathways. This review focuses on the current knowledge and recent advances in our understanding of cyTreg and their potential application in the treatment of human disease, particularly Graft-versus-Host Disease (GVHD). Regulatory T cells (Treg) play a complex multifaceted role in maintaining immune homeostasis and promoting tolerance at steady state. Treg are widely regarded to engage in various suppressive mechanisms directed against T-cells and antigen presenting cells (APC). Since their discovery, CD4 + CD25 + T-cells have been found to protect against autoimmune disease (1) and are known to be critical for tolerance against alloresponses in vivo (2) including bone marrow and solid organ transplantation tolerance in allogeneic murine recipients (3) (4) (5) . Adoptive transfer of Treg with alloreactive T-cells have shown efficacy in limiting the Graft-Versus-Host Disease (GVHD) response in preclinical transplant models, and Graft-versus-Leukemia (GVL) responses have byand-large, but not uniformly, remained intact (6) (7) (8) . Clinical trials have demonstrated that Treg infusion during allogeneic hematopoietic stem cell transplantation (alloHSCT) can reduce and treat GVHD (9) (10) (11) (12) (13) (14) . Decisive conclusions on post-transplant relapse rates await randomized trials. To date, current studies observing high-risk acute leukemia adult patients treated by haploidentical transplantation with an infusion of Foxp3 + Treg four days prior to T-cells have shown similar reductions in GVHD occurrence and severity as previous studies and the cumulative incidence of relapse was significantly lower than their historical controls (11) (12) (13) . This balance between ameliorating GVHD while preserving GVL continues to be a major consideration for the development of effective GVHD treatments. Recent data has come to light that subsets of cytotoxic effector Treg (cyTreg) may have a unique application here and are capable of suppressing GVHD while effectively preserving GVL activity (8, (15) (16) (17) . Studies dating back to the early 2000s demonstrated that Treg engage in cytolytic activities. While cytolysis is a well characterized mechanism of conventional cytotoxic T effector cells (Teffs) and natural killer (NK) cells, it was surprising to find that Treg also engaged in directed killing of target cells to suppress immune responses while maintaining traditional suppressive capabilities (18, 19) . Before cytolysis was directly ascribed as a mechanism of suppression by Treg, cytolysis had been reported as a critical pathway for immune homeostasis as its been documented that mutations in killing pathways are associated with many autoimmune and inflammatory diseases, including autoimmune lymphoproliferative syndrome (ALPS) (20) (21) (22) (23) and Griscelli's syndrome (24) (25) (26) . There is now a growing repository of data supporting the important role of cytotoxicity in cyTreg for immune regulation and disease control. In this review, we discuss the current and growing knowledge of cyTreg, the directed killing and immunosuppressive mechanisms that drive their function, and their potential clinical applications for the treatment of human disease, including cancer, inflammatory disease and GVHD. The primary function of Treg is to maintain immune homeostasis and self-tolerance by modulating the activity of effector lymphocyte populations. Traditionally, both CD4 + and CD8 + Treg have been recognized to impart immunosuppressive effects through contact dependent and independent mechanisms. For example, CTLA-4 expression by Treg is recognized as an integral marker of contact dependent immunosuppression. CTLA-4 is known to inhibit T-cell activation and expansion by both directly engaging with CD28 on the surface of T-cells to block co-stimulation, and by cleaving CD80/CD86 from the surface of APC to further inhibit APC/T-cell interactions (27) (28) (29) (30) (31) . In addition to contact dependent pathways, Treg have also been shown to suppress T-cell activity through the release of soluble factors, such as IL-10 and TGF-b. IL-10 is produced by several immune cell populations, including Treg and has been shown to be important for preventing mucosal inflammation and autoimmunity (32) (33) (34) . IL-10 is known to suppress the activity of T-cells by inhibiting the APC expression of MHC class II and CD80/86 and the production of proinflammatory cytokines (IL1a, IL1b, IL-12, IL-18, TNFa) and chemokines (MCP1, MCP5, RANTES, IP-10, IL-8, and MIP-2), as well as impeding T-cell proliferation and cytokine production (IL-2, IFNg, IL-4, IL-5, TNFa). Similarly, TGF-b production has also been shown to be important in modulating inflammation (35) (36) (37) , and the contact-dependent function of TGF-b has been well-described to orchestrate the induction and maintenance of peripheral Treg (pTreg) (38, 39) , induced Treg (iTreg) (38, 40) , and invariant natural killer T-cells (iNKT) (41, 42) . Several studies have highlighted the suppressive activity of Treg-derived TGF-b, which has been reported to inhibit both NK and Teff cytotoxic activity (43) (44) (45) . Interestingly, both IL-10 and TGF-b signaling have also been reported to play a role in cytotoxicity. While TGFb has been shown to drive the induction of CD103 expression in CD8 + iTreg, which in some circumstances has been shown to be a simultaneously cytotoxic and immunosuppressive T-cell subset (46) , IL-10 has also demonstrated cytolytic characteristics during systemic lupus erythematosus (SLE) (47) (48) (49) . IL-10 produced by B cells and monocytes can induce Fas/FasL expression on cell surfaces of various immune cells, including T-cells to cause apoptosis via caspase 8 activation (47, 48) . IL-10 induced Fas/ FasL pathway is important for disease control and has otherwise been an under reported functional mechanism of IL-10 signaling ( Figure 1 ) (50) (51) (52) . Similarly, IL-10 has also been shown to induce the production of cytotoxic enzymes and IFNg in CD8 + T-cells, and, in conjunction with IL-2, differentiation of cytotoxic T-cells from their precursors, demonstrating a dual function of IL-10 signaling in immune regulation (53, 54) . Treg can be classified into subtypes based on their phenotypic profiles, cytokine production, and expression of lineage defining transcription factors such T-bet and RORgt (55) . With the use of advanced sequencing technologies, we are expanding our understanding of the similarities and unique aspects of Treg subtypes based on their transcriptome (56, 57) . Höllbacher et al. (2020) (58) performed RNA sequencing on Treg and found that subtypes clustered together, although with notable differences, suggesting lower diversity amongst Treg as compared to CD4 + T helper cells (Th). For example, expression of IL-10 was limited to only a few Treg subtypes which included Th1-like Treg and Th17-like Treg. Th1-like Treg also had the highest expression of the coinhibitory receptors TIM3 and LAG3, and the cytolytic molecules GZMA and GZMB (58). In contrast, other genes associated with Treg suppressive function such as CTLA4, PDCD1, TIGIT, and PRF1, were not preferentially expressed by any Treg subtype (58) . Furthermore, single cell RNA sequencing demonstrates Treg clustering within lymphoid tissues into central versus effector Treg populations, and within nonlymphoid tissues into multiple other Treg populations that represent tissue adaptation and local immune control (56) . For example, in the colon of healthy mice there were three clusters of Treg, two which expressed genes associated with Th2 and immunoregulatory and immune suppressive Th3 lineages (56) . These findings suggest each Treg subset may have a specialized mechanism to modulate specific types of immune responses, and that some may have a greater potential to engage in cytolytic mechanisms. Several subsets of CD4 + and CD8 + Treg have been reported to engaged in directed killing of target cells through perforin and granzyme mechanisms. Perforin is a glycoprotein that polymerizes to form channels within target cell membranes (59, 60) . These channels allow for free and non-selective transport of ions, water, and other molecules including proapoptotic granzymes, which disrupts cell homeostasis and cause cell death (59, 61) . While Teff and NK cells are major sources of perforin and granzymes, which are released from cytoplasmic granules upon recognition of target cell (62), cyTreg have also been shown to produce perforin and granzymes ( Figure 1 ) (18, 19, 27, 63) . Granzymes are highly conserved serine proteases that make up the majority of the cytoplasmic granules of Teff and NK cells. While NK cells constitutively express and store granzymes, other T-cell subsets (i.e. CD4 + T-cell, CD4 + Treg) must be activated to produce granzymes (64, 65) . Granzymes maintain both cytotoxic and non-cytotoxic mechanisms to regulate immune responses. Ten granzymes have been discovered in mice, of which five are known in humans; these differ in their primary substrate specificities within target cells (66) . Granzyme A (GzA) and B (GzB) are the most abundant and therefore the most frequently studied. GzA activates caspase-independent programmed cell death through cleavage of intracellular substrates, including mitochondrial complex I substrate NDUFS3 and precursor IL-1b ( Figure 1 ) (67) (68) (69) (70) . GzB promotes apoptosis through the BH3-interacting domain death agonist (Bid), a proapoptotic Bcl-2 family member, by inducing mitochondrial permeabilization or direct proteolysis and activation of caspases ( Figure 1 ) (71, 72) . Though yet to be studied in Treg, special attention should be brought to the formation of supramolecular attack particles (SMAPs) by Teff (73) and NK cells (74) that allow for hours of sustained killing. Cytotoxic T-cell SMAPs are multiprotein complexes assembled from over 285 different proteins including cell adhesion molecules, chemokines, cytokines, and cytolytic perforin, granzymes, and galectin-1 stored within secretory lysosomes of cytolytic lymphocytes (73, 74) . SMAPs are contained within a shell rich in glycoproteins, including perforin, granzymes and thrombospondin-1, that interact with target cells to theoretically allow autonomous killing by SMAPs, promoting killing during interactions that are transient or less precise (73) . While many of these cytotoxic mechanisms are well described in Teff and NK cells, there are important roles for these functional pathways in cyTreg function, which we discuss throughout this review. Although the role of many of these pathways in cyTreg remain unclear, there appears to be an intricate system of regulation for cyTreg to engage in killing and/or immunosuppressive functions in vitro and in vivo. CD4 + CD25 + Foxp3 + Treg are essential for maintaining immune homeostasis, preventing autoimmunity, and promoting tolerance (75) . There are three major subsets of CD4 + Treg: thymic derived Treg (tTreg), Treg that are induced in the periphery from CD4 + Foxp3 neg conventional T-cells (pTreg), and Treg generated in vitro from CD4 + Foxp3 neg conventional T-cells using TGF-b and IL-2 (iTreg) (76) . Treg have been reported to engage in multiple contact-dependent and independent mechanisms. These mechanisms can directly suppress immune cells or function indirectly by modulating APC and/or generating an anti-inflammatory milieu (77) (78) (79) . For example, Treg can modulate APC through CTLA-4, suppress multiple cell types through secretion of anti-inflammatory cytokines (IL-10, TGF-b, IL-35), suppress T-cells via IL-2 consumption, use cytolytic pathways to kill T-cells or APC, and generate immunosuppressive environments through adenosine production via the ectoenzymes CD39 and CD73 (77) ( Table 1) . While mouse studies have provided insights into the various mechanisms available for CD4 + Treg, the importance of these pathways in regulating immune tolerance is further supported in clinical reports of patients with inborn errors of immunity. For example, patients with CTLA-4 haploinsufficiency experience immune dysregulation and deficiency with a spectrum of clinical manifestations that can include lymphoproliferation and autoimmunity targeting multiple organs such as the lungs, gastrointestinal tract, brain, bone marrow, kidney, hypophysis, and thyroid (92, 93) . Importantly, these patients had either normal or elevated numbers of Treg, but CTLA-4 protein expression was significantly decreased on Treg and this was associated with impaired Treg suppressive function (92, 93) . Patients with mutations in the Treg master transcription factor FOXP3 that preclude CD4 + Treg generation or function experience immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome with onset in early life and a high mortality rate (106) (107) (108) (109) . Treg have constitutive expression of the alpha subunit (CD25, or IL-2RA) of the trimeric IL-2R which allows them to uptake IL-2 more readily during an immune response and engage in a positive feedback cycle whereby IL-2 promotes Foxp3 expression in Treg (110) . Patients with mutations in IL2RA can have severe enteritis, viral infection susceptibility, pronounced lymphoproliferation, autoimmunity, and an IPEX-like syndrome (94, 95, 111) (94, 95, (106) (107) (108) (109) . IL-10 signaling has been particularly important for tolerance induction in the gut, as patients with loss of function mutations in IL-10 or IL-10R develop very early onset severe inflammatory bowel disease (96, 97) . While loss of IL-10 signaling affects Treg suppressive function on multiple cell types including T-cells leading to GI disease, there is evidence Human GzB dependent killing Perforin dependent killing IL-10 and TGF-b mediated suppression (19, (103) (104) (105) demonstrating that patients with IL-10R mutations fail to augment iTreg formation compared to healthy controls (112) . Lastly, the immune regulatory role of perforin is demonstrated in patients with monoallelic perforin gene mutations resulting in partial degranulation defects that only present complications following an infection or other immune trigger such as cancer, whereby patients are unable to mount an appropriate immunological response (113) . Thus, the role of perforin may be important for Treg mediated immune tolerance but may not be as critical as is the expression of other genes such as CTLA-4 and FOXP3 based upon the clinical consequences of loss-offunction defects. Interestingly, the exact mechanisms used by CD4 + Treg to suppress remains incompletely understood, particularly in vivo. Treg dependency on different mechanisms in vitro and in vivo is likely attributed to the fact that different kinds of suppression might be necessary depending on the type, timing, intensity and duration of inflammation, and anatomical site of the immune reaction, as well as which cell needs to be suppressed i.e. T-cells, B cells, or APC. Here we review the role and importance of cytolysis as a mechanism of CD4 + Treg to module immune responses. An early study by (18) demonstrated that following activation, human CD4 + tTreg expressed the tryptase GzA, whereas CD4 + pTreg expressed the serine protease GzB. Both CD4 + Treg subtypes were shown to kill autologous target cells in vitro in a perforin and CD18 dependent manner, suggesting that the interaction via the immunological synapse was necessary for cytotoxicity to occur ( Table 1 ). They also demonstrated that activated T-cells and immature dendritic cells (DCs) were preferentially killed compared to resting Tcells and mature DCs, indicating that not all target cells have equivalent susceptibility to CD4 + Treg mediated killing (18) . Interestingly, CD4 + tTreg had more potent in vitro killing compared to CD4 + pTreg (18) . Differential granzyme expression and killing potential between Treg subsets suggest each subtype may have different roles in immune regulation. Notably, granzyme expression patterns also differ between different human T-cells subsets. While most resting NK cells and approximately half of CD8 + T-cells coexpress GzA and GzB, very few resting CD4 + T-cells express both GzA and GzB (19) . Unstimulated, freshly isolated human CD4 + Treg and CD4 + CD25 neg T-cells express little to no GzB or perforin expression (18) . Naive CD4 + T-cell activation with IL-2 alone leads to minor GzB expression, while activation with CD3/CD28 beads leads to intermediate percentage of GzB expressing cells with no GzA expression (19) . The quantity of granzymes expressed based on level of activation in the different T-cell subsets supports the idea that some cells are more readily equipped to engage in cytolytic pathways. These data raise many questions that need to be further investigated such as: is the differential killing potential between CD4 + tTreg and pTreg associated with the differential granzyme expression? Why is it advantageous for human CD4 + tTreg to express GzA and CD4 + pTreg to express GzB? Similar to human CD4 + Treg, freshly isolated murine CD4 + tTreg also have little to no GzB or perforin expression (80) . The expression of these molecules is upregulated following activation with slower kinetics and quantity compared to that of CD8 + T-cells, and with greater quantity compared to that of CD4 + CD25 neg T-cells (80) . GzB deficient murine CD4 + tTreg showed reduced suppression of T-cell proliferation when compared to wildtype and perforin deficient CD4 + tTreg; suppression in this assay was due to increased T-cell apoptosis ( Table 1 ) (81) . It is unfortunate that GzA expression or its role in murine CD4 + tTreg killing was not evaluated in this particular study, as previous human CD4 + tTreg studies showed preferential expression for GzA (18) . Furthermore, these results differ from the study which showed human CD4 + Treg killing occurred in a perforin dependent mechanism; although notably the role of GzB was not evaluated (18) . The mechanism by which GzB mediates cytolysis in the absence of perforin has yet to be fully described (81) . It has been shown that GzB in the extracellular space can induce apoptosis of smooth muscle cells, offering an alternative pathway by which Treg can induce target cell death (114) . Furthermore, it's possible that Treg induced mechanical movement alone can induce necrosis of target cells, as killing in this form has been reported in the absence of perforin in T-cells (115) . Altogether, these data demonstrate CD4 + Treg express killing molecules following activation and engage in cytolysis of immune cells through either a perforin or GzB dependent process. It is challenging to fully grasp the role perforin, GzB, and GzA in Treg killing, as each study typically measured the expression and tested the mechanistic role of only some of these molecules. For example, GzA is rarely investigated in Treg killing literature. While it was originally known that CD4 + tTreg cells could directly suppress B cell proliferation, Ig production, and class switch recombination (116, 117) , the exact mechanism used to suppress had not been described. Zhao et al. (2006) (80) demonstrated that activated murine CD4 + CD25 + tTreg suppressed B cell proliferation in a cell contact-dependent, cytokine independent manner that was dependent on the upregulation of perforin and granzymes, and independent of the death receptors, Fas and TRAILR. They demonstrated that activated CD4 + CD25 + tTreg preferentially killed antigen presenting B cells compared to resting bystander B cells in a GzB dependent, partially perforin dependent manner ( Table 1 ) (80). They found freshly isolated CD4 + CD25 + tTreg had little to no granzyme expression and could not engage in killing of B cells, but could potently suppress in vitro T-cell proliferation (80) . In contrast, pre-activated CD4 + CD25 + tTreg had increased expression of GzB and became licensed to kill B cells, but not T-cells (80) . Why murine CD4 + tTreg in this study failed to kill T-cells is unclear as (81) . It's possible that higher levels of activation were required to trigger sufficient perforin and granzyme molecule expression in order to stimulate T-cell killing. In summary, CD4 + tTreg use the perforin granzyme pathway to suppress B cell immune responses. While CD4 + Treg had been reported to kill autologous immune cells, Choi et al. (2013) (98) was the first to explore whether CD4 + tTreg could co-opt this strategy to kill malignant cells. The idea that CD4 + Treg can be utilized to enhance antitumor immunity is paradigm shifting as Treg are associated with suppression of desired anti-tumor or anti-infectious responses. Choi et al. (2013) (98) demonstrated that an EGFRvIII-specific bispecific T-cell engager (BiTE) could redirect human CD4 + CD25 + CD127 dim/-Foxp3 + Treg and activate them in the presence of glioblastoma tumors expressing EGFRvIII. While human CD4 + CD25 + CD127 dim/-Foxp3 + Treg are known to be highly suppressive, these Treg showed increased expression of perforin, GzA, and GzB after activation (98) . Furthermore, they potently lysed EGFRvIII + tumor cells in vitro in the presence of EGFRvIII-specific BiTE and failed to lyse tumor in the presence of a non-specific BiTE, or when Treg were cultured in the absence of BiTEs. These human CD4 + tTreg killed EGFRvIII tumor cells in a perforin-dependent, partially GzB-dependent manner (98) . Lastly, GzB + Foxp3 + cells were identified in human primary glioblastoma tissues suggesting a potential role of cyTreg in the tumor microenvironment (TME) not previously recognized (98) . Research will be necessary to determine which type of cyTreg, whether CD4 + pTreg or tTreg, would be more effective killers in the TME, and to determine what engages the cytolytic potential versus other suppressive mechanisms against tumor cells. Altogether, these data suggest that BiTEs, and potentially other therapies such as Chimeric Antigen Receptors (CAR), have the potential to redirect suppressive Treg to induce their cytolytic potential against tumor cells in an effort to promote anti-tumor responses. Whether CD4 + Treg redirected with BiTEs or CARs can engage in anti-tumor responses in vivo will need to be investigated. Multiple groups had shown the role of the perforin and granzyme pathways in CD4 + cyTreg mediated suppression in vitro. However, it was unknown whether CD4 + cyTreg also regulated immune responses in vivo. Cao et al. (2007) (99) tested this idea using multiple tumor models and donor mice deficient in GzA, GzB, and perforin. They found that murine CD4 + Treg isolated from the TME upregulated GzB, but not GzA, and that perforin and GzB deficiency were essential in dampening anti-tumor responses in vivo (99) . They further demonstrated in ex vivo experiments that murine CD4 + Treg derived from tumors killed NK and CD8 T-cells in a perforin, GzB dependent manner ( Table 1 ) (99) . This was the first report of CD4 + cyTreg using cytolysis similar to NK and CD8 + T-cells to suppress immune responses in vivo. Boissonnas et al. (2010) (82) further demonstrated the cytolytic potential of CD4 + cyTreg in anti-tumor responses using two-photon microscopy in explanted tumor draining lymph nodes (LN) to show that DC death only occurred when perforin sufficient Foxp3 + Treg were present and in the presence of tumor antigens ( Table 1) . A limitation of this study was the measured expression of both GzB and perforin in CD4 + Treg without mention of GzA, and the use of only perforin KO mice for in vivo studies. Thus, more research will be needed to understand GzA expression of CD4 + cyTreg in tumor models, determine the exact role of GzA and GzB for in vivo suppression, and evaluate CD4 + cyTreg anti-tumor potential in vivo. Altogether, these data suggest that CD4 + Treg utilize granzyme and perforin pathways to suppress anti-tumor responses in vivo. To further support the role of cytolytic pathways in Treg suppression in vivo, Gondek et al. (2008) (83) demonstrated murine CD4 + tTreg initiated and maintained allograft tolerance in a GzB dependent, perforin independent manner. These results are in contrast with the two studies above which found Treg mediated killing was perforin dependent. Furthermore, gene expression analysis showed that mouse CD4 + Foxp3 + iTreg expressed GzB, GzC, Fas-L, and DAPK2 (death-associated protein kinase 2) albeit at lower levels compared to CD8 + Foxp3 + iTreg. These results were supported through in vivo findings whereby CD4 + iTreg suppressed GVHD but abrogated GVL effects (8) . Thus, the cytolytic potential of CD4 + iTreg compared to CD4 + tTreg in vivo will need to be evaluated. Lastly, Loebbermann et al. (2012) (84) sought to evaluate whether pulmonary responses were regulated by Treg during acute RSV infection in mice and found GzB deficiency in Treg worsened pulmonary pathology, suggesting GzB dependent suppression of lung inflammation during acute viral lung infection ( Table 1) . Unfortunately, they did not measure perforin or GzA expression of these Treg in the lungs or use KO mice to evaluate the role of these other killer molecules. In summary, these data suggest CD4 + Treg can use the perforin and/ or granzyme pathway in vitro and in vivo, and have the potential to target DCs, B cells, T-cells, NK cells, and tumor cells to control immune responses (Figure 1 ). Cytotoxic cells have mechanisms in place to prevent self-inflicting apoptosis from cytotoxic granule contents by expression of serine protease inhibitors called serpins. Serpin 6 (Spi6) has been demonstrated to protect murine Teff, DCs, and Treg from granzyme induced cytotoxicity (118) (119) (120) . Similarly, the human equivalent of Spi6 is proteinase inhibitor 9 (PI9) and has been shown to be upregulated concurrently with GzB expression (121) . Interestingly, Sula et al. (2017) (122) found that Treg from patients undergoing renal graft rejection, or Treg in vitro stimulated from healthy donors, had higher levels of GzB expression and higher GzB expression was shown to increase Treg apoptosis despite PI9 co-expression (122) . Why PI9 was not protective of human Treg in this particular study will need to be further evaluated. Are these results due to differences between mouse and human Treg, or it may be possible that in these settings there was more GzB production than PI9 could neutralize? These data suggest that the granzyme-perforin pathway functions are a mechanism to suppress other target cells but also may serve as a mechanism for Treg activation induced cell death. While we highlight studies that report killing as a mechanism of CD4 + Treg suppression, many Treg studies have found noncytolytic mechanisms to be essential (78) . A key factor that may help explain differences in regard to GzB expression and killing as a suppressive mechanism in Treg is whether rapamycin was used in Treg cultures to promote purity. Treg activated with anti-CD3, anti-CD28, IL-2 and rapamycin have lower levels of GzB expression when compared to Treg cultured in the absence of rapamycin; additionally, the lower expression of GzB was shown to be correlated with decreased levels of cytotoxicity (123) . These results suggest that Treg cultured with rapamycin are likely to engage in other mechanisms of suppression outside the perforin-GzB pathway. Additionally, the measured killing by CD4 + Treg has been thought by some groups to be mediated by contaminating Teff. While the early studies used CD4 + CD25 + and CD4 + CD25 neg to differentiate Treg versus CD4 + T-cells, many noted key Treg characteristics such as constitutive CD25 expression and lack of IL-2 production or sorted out the top 2% of CD4 + CD25 + T-cells to purposely gate out as many contaminating CD4 + T-cells (18, 100) . Furthermore, in the Choi et al. (2013) (98) studies the Treg used for in vitro killing assays were first tested for in vitro suppressive function and were then used for in vitro killing assays with >95% Foxp3 + . Thus, there is sufficient data to support CD4 + Treg can engage killing pathways in order suppress immune responses. While the granzyme-perforin pathway appears to be important in CD4 + tTreg mediated control of immune responses, we must consider the role of other reported killing pathways. In an early report by Janssens et al. (2003) (100) murine CD4 + CD25 + Treg were shown to be dependent on the Fas/FasL pathway to lyse APCs in an antigen-specific and MHC class II restricted manner (Table 1; Figure 1 ). These results showed that killing was a mechanism used by Treg to exert suppressive effects on APCs and bystander T-cells. Another mechanism of killing used by Treg is the tumor necrosis factor related apoptosis ligand (TRAIL)/death receptor 5 (DR5) pathway. Ren et al. (2007) (85) demonstrated that murine CD4 + Treg are dependent on the TRAIL/DR5 pathway to mediate both suppression and cytotoxicity in vitro and in vivo ( Table 1) . Using DR5 blocking antibodies, they showed CD4 + Treg used cytolysis to prolong tolerance to allogeneic skin grafts by killing CD4 + T-cells ( Figure 1 ) (85) . Lastly, whether CD4 + Treg use galectin-1 induced cell death to suppress effector T-cells in vivo will have to be further evaluated (124) . Together, the current literature suggests that mouse and human CD4 + cyTreg predominantly engage in the perforin granzyme pathway, with some reported instances using the Fas/ FasL and TRAIL/DR5 pathways. However, how CD4 + cyTreg choose one killing pathway versus another, and elucidating when they decide to engage in killing versus other suppressive mechanism warrants further investigation. Type 1 regulatory (Tr1) cells are a T-cell subset characterized as Foxp3 neg , CD49b + , and Lag3+ that produce high levels of IL-10 along with TGF-b, IFNg, IL-5, and are IL-4and IL-2 low/- (125) . While Tr1 cells are well recognized to suppress immune responses in cytokine dependent mechanisms via IL-10 and TGF-b (126, 127) , Tr1 cells have also been found to engage in contact-dependent mechanisms including the PD1/PDL-1 and CTLA-4/ CD80 pathways (128) . Interestingly, Tr1 have also been found to kill myeloid cells through the perforin-granzyme pathway in an antigen dependent and independent manner ( (19) showed that human naive CD4 + T-cells stimulated with anti-CD3/CD46 antibody to generate Tr1 IL-10 producing cells led to expression of GzB in over 90% of the cells with no GzA expression, while anti-CD3/CD28 antibody mediated activation did not induce GzB expression. Based on this GzB expression pattern it was not surprising they found Tr1 cells showed maximal killing, whereas IL-2 activated CD4 + T-cells which had significantly lower levels of GzB expression showed minimal killing. These GzB + Tr1 cells engage in perforin-dependent, MHC/TCR independent killing of allogeneic myeloid leukemia cell lines in vitro ( Table 1 ) (19) . In an effort to enhance Tr1 cell therapy, Roncarolo, who first identified Tr1 cells, and colleagues recently developed engineered human Tr1 cells by lentiviral transduction of IL-10 into peripheral CD4 + T-cells. This group found that these engineered human Tr1 cells had the ability to kill pediatric and adult acute myeloid leukemia (AML) cells (15, 130) . Importantly, Tr1 cells retained their suppressive functions in vivo by suppressing GVHD and maintaining GVL responses (15) . These data are exciting as it offers a cellular approach that is capable of both suppressing GVHD responses while concurrently potentiating GVL responses. How we can further enhance this type of bifunctional therapy will need to be evaluated as this approach can significantly address key limitations of Treg therapy for alloHSCT. In summary, Tr1 cells use the perforin granzyme pathway to suppress immune responses by targeting nonmalignant myeloid cells and potentiate anti-tumor responses by killing malignant myeloid cells. CD8 + Treg represent another repository of cyTreg that remains substantially understudied. CD8 + Treg are loosely defined as a heterogenous population of CD8 + lymphocytes that can express several Treg associated surface markers and have immunosuppressive capacity, thus defining them as a Treg subset (131) (132) (133) . CD8 + Treg have been reported to express a range of Treg markers such as CD122, CD25, CD103, GITR, CTLA-4, and PD1, and to engage in a range of cell contact-dependent and independent mechanisms to suppress immune responses ( Table 2 ) (27, 134, 137, 138, (162) (163) (164) . However, due to their low frequency in vivo and lack of conserved and consistent phenotypic markers, CD8 + Treg have yet to be fully described (163) . Like CD4 + Treg, CD8 + Treg are capable of inhibiting the activity of Teff. CD8 + Treg have been demonstrated to modulate Teff activation and proliferation through the release of immunosuppressive cytokines, including IL-10 and TGF-b (165), as well as inhibitory cell-to-cell interactions through CTLA-4 and PD-1 signaling pathways (166). Furthermore, the suppressive activity of CD8 + Treg in vivo has been shown to be important in regulating normal immune function and preventing inflammatory disease in humans, including inflammatory bowel disease, autoimmune diabetes, multiple sclerosis, and GVHD (167) (168) (169) . In addition to their immunosuppressive capabilities, several subsets of CD8 + Treg have been described to utilize both suppressive and cytotoxic functions (CD8 + cyTreg), including both Foxp3 + and Foxp3 neg CD8 + Treg subsets described below. In fact, CD8 + cyTreg have been reported to utilize directed killing pathways as key mechanism to inhibit Teff activity (170) . However, as the circulating frequency of CD8 + Treg is extremely low in both mouse and human (164) , the vast majority of current literature focuses on different subsets of ex vivo generated CD8 + iTreg. As such, CD8 + cyTreg represent an extremely heterogenous population in vivo, and the precise mechanisms of suppression and/or killing utilized by these cell populations are highly dependent on the CD8 + cyTreg phenotype and local environmental stimuli (163, 171) . The bifunctionality of CD8 + cyTreg remains highly debated in the literature and warrants further investigation. CCD8 + Foxp3 + Treg CD4 + Treg are well defined by constitutive expression of Foxp3, the master regulator of Treg suppressive function (172) (173) (174) . Similarly, both murine and human studies have also described Foxp3 expression in several subsets of CD8 + Treg, including CD8 + CD25 + Foxp3 + , CD8 + Foxp3 + Lag3 + , and CD8 + CD103 + Foxp3 + Treg (155, 175) . In fact, several groups argue that Foxp3 expression in CD8 + T-cells is a highly conserved marker of CD8 + Treg (164, (176) (177) (178) . CD8 + Foxp3 + Treg have been shown to be highly immunosuppressive and in some circumstances have been shown to employ cytotoxic killing pathways as an additional mechanism of immunosuppression. In mice, CD8 + CD25 + Foxp3 + Treg have even been shown to be equally, if not more, suppressive in vitro than an equivalent CD4 + Treg (164) . Therefore, CD8 + Foxp3 + Treg have gained substantial interest as a unique cell type that may have applications in the treatment of some cancers, as well as autoimmune and inflammatory disease. There are several subsets of CD8 + T-cells that have been reported to express Foxp3. CD8 + CD25 + Foxp3 + Treg are the most phenotypically and functionally similar to CD4 + Treg. Like their GzB, granzyme B; GzA, granzyme A; ILT3/ILT4, immunoglobulin-like transcripts 3 and 4; CCL4, chemokine (C-C motif) ligands 4; IEL, Intraepithelial lymphocytes. Symbols: +/-pathway or marker is shown to be intermittently applicable or inconsistently reported between multiple studies. +>-pathways is most often shown to be applicable. +